September 30, 2021
1 min watch
Save
VIDEO: Efficacy shown, toxicity a factor for DS-7300
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discusses a phase I/II multicenter first-in-human trial of DS-7300, an anti-B7-H3, which was studied in patients with advanced solid tumors.
"There was efficacy shown, just like with the MGC018, though the toxicity is going to be a key factor of applicability of the agent into clinical practice," Shenderov said.
Published by:
Sources/Disclosures
Collapse
Source:
Johnson ML, et al. Abstract 5130. Presented at: ESMO 2021; Sept. 16-21, 2021 (virtual meeting).
Disclosures:
Shenderov reports receiving clinical trial institutional research funding from MacroGenics; is the founder and CEO of LifeImmune, Inc; and has served as a consultant for Firstthought and Guidepoint Global.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.